FIELD: medicine.
SUBSTANCE: application of Aplidine for obtaining of a medicine for treatment myeloma (M), corresponding method of M treatment and pharmaceutical composition of the same administration is offered. It is shown, that Aplidine not only reduces viability of M cellular lines, but also reduces secretion of growth factors of an epithelium of blood vessels, interfering with myeloma diffusion, raises sensibility of myeloma cells to Doxorubicin chemotherapy.
EFFECT: obtaining of an agent reducing viability of myeloma cellular lines and raising sensitivity of myeloma cells to Doxorubicin chemotherapy.
3 cl, 6 ex, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED METHODS FOR TREATING TUMOURS | 2007 |
|
RU2481853C2 |
| METHOD FOR IMPROVING TARGETED ACTION OF CD138 EXPRESSING TUMOUR CELLS AND AGENTS TO THIS EFFECT | 2008 |
|
RU2486203C2 |
| TREATMENT OF MALIGNANT TUMOR WITH APLIDINE | 2000 |
|
RU2261104C2 |
| APPLICATIONS OF IMMUNOCONJUGATES WITH CD138 AS TARGET | 2010 |
|
RU2561041C2 |
| APPLICATIONS OF IMMUNOCONJUGATES, THE TARGET OF WHICH IS CD138 | 2012 |
|
RU2632108C2 |
| ANTI-CD138 IMMUNOCONJUGATES AND USING THEM | 2008 |
|
RU2547939C2 |
| BIOLOGICAL MATERIALS AND USE THEREOF | 2011 |
|
RU2593709C2 |
| HEMOPOIETIC CELL CD34+ AND USE THEREOF | 2005 |
|
RU2390558C2 |
| COMPOSITIONS AND METHODS FOR TREATING DISEASE | 2007 |
|
RU2482877C2 |
| HUMANISED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2013 |
|
RU2551235C2 |
